EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Longitudinal Assessment of 4‐Year HFMSE Changes in SMA II and III Patients Treated With Nusinersen

Giorgia Coratti iD, Francesca Bovis, Marika Pane, Amy Pasternak, Emilio Albamonte, Irene Mizzoni, Allan M Glanzman, Simone Morando, Jacqueline Montes, Ilaria Cavallina, Sally Dunaway Young, Tina Duong und 23 weitere

European Journal of Neurology · 2025-07 · 32 (7)

DOI: 10.1111/ene.70268 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 27.06.2025. Verfasst von Giorgia Coratti und 34 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Neurology Unit, Catholic University of Sacred Heart, Rome, Italy. Hauptthemen laut MEDLINE: Oligonucleotides, Spinal Muscular Atrophies of Childhood. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministero della Salute, Biogen, Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The aim of this international retrospective study was to assess 4‐year change using the Hammersmith Functional Motor Scale Expanded (HFMSE) in individuals with type II and III spinal muscular atrophy (SMA) treated with nusinersen and to establish predictors of HFMSE changes.

Methods

Individuals with type II or III SMA, and at least 4 years of nusinersen‐only treatment were included. All were assessed using the HFMSE. Age at baseline, sex, motor function, SMN2 copy number, and age of onset were also retrospectively collected. Linear mixed effect models were used to calculate yearly changes and trajectory predictors.

Results

We included 73 individuals with SMA type II (mean age 8.58 years, SD 7.91, IQR 3.04–10.70) and 111 type III (mean age 7.91 years, SD 17.83, IQR 8.15–34.42). Over 4 years, mean changes were + 4.18 (95% CI: 2.85–5.50) for SMA II and + 1.08 (95% CI: 0.12–2.04) for SMA III. Age (SMA II: −0.34\[−0.51 to −0.17]; SMA III: −0.13\[−0.20 to −0.06], p < 0.001) and baseline HFMSE (SMA II: 1.02\[0.70–1.34]; SMA III: 0.79\[0.71–0.87], p < 0.001) were the strongest predictors of progression, with younger age and higher baseline scores associated with better outcomes. Functional status was only predictive for type III (6.96\[4.26–9.66]).

Conclusion

Our results confirm that, given a follow up of 4 years, there is a persistent impact of nusinersen on clinical progression that is better observed in younger patients with higher HFMSE scores at baseline, especially during the first 2 years of treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OligonucleotidesSpinal Muscular Atrophies of ChildhoodHumansMaleFemaleChildRetrospective StudiesChild, PreschoolLongitudinal StudiesAdolescentAdultDisease ProgressionYoung AdultTreatment OutcomeSurvival of Motor Neuron 2 ProteinSeverity of Illness Index

Stichwörter der Autor:innen

Hammersmith functional motor scale expandedlong term resultsmotor functionnusinersenspinal muscular atrophy

Substanzen

nusinersenOligonucleotidesSurvival of Motor Neuron 2 Protein

Autor:innen und Institutionen

  • Pediatric Neurology Unit, Catholic University of Sacred Heart, Rome, Italy.
  • Centro Clinico Nemo, U.O.C. Neuropsichiatria Infantile, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
  • Neuromuscular Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • The NEMO Center in Milan, Neurorehabilitation Unit, University of Milan, ASST Niguarda Hospital, Milan, Italy.
  • Unit of Neuromuscular and Neurodegenerative Disorders, Translational Paediatrics and Clinical Genetics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

ORCID-Profile: Giorgia Coratti, Giulio Gadaleta

Förderung

  • Ministero della Salute
  • Biogen
  • Novartis
  • Roche

Zitieren

APA

Coratti, G., Bovis, F., Pane, M., Pasternak, A., Albamonte, E., Mizzoni, I., Glanzman, A. M., Morando, S., Montes, J., Cavallina, I., Dunaway Young, S., Duong, T., Rolle, E., Civitello, M., De Sanctis, R., Bravetti, C., Ricci, F., Gadaleta, G., Mongini, T., …, & iSMAC/international SMA consortium (2025). Longitudinal Assessment of 4‐Year HFMSE Changes in SMA II and III Patients Treated With Nusinersen. European Journal of Neurology, 32(7). https://doi.org/10.1111/ene.70268

Vancouver

Coratti G, Bovis F, Pane M, Pasternak A, Albamonte E, Mizzoni I, et al. Longitudinal Assessment of 4‐Year HFMSE Changes in SMA II and III Patients Treated With Nusinersen. European Journal of Neurology. 2025;32(7). doi:10.1111/ene.70268

BibTeX
@article{Coratti2025,
  author = {Coratti, Giorgia and Bovis, Francesca and Pane, Marika and Pasternak, Amy and Albamonte, Emilio and Mizzoni, Irene and Glanzman, Allan M and Morando, Simone and Montes, Jacqueline and Cavallina, Ilaria and Dunaway Young, Sally and Duong, Tina and Rolle, Enrica and Civitello, Matthew and De Sanctis, Roberto and Bravetti, Chiara and Ricci, Federica and Gadaleta, Giulio and Mongini, Tiziana and Sframeli, Maria and Pera, Maria Carmela and Messina, Sonia and D'Amico, Adele and Catteruccia, Michela and Brolatti, Noemi and Hirano, Michio and Zolkipli-Cunningham, Zarazuela and Darras, Basil T and Bertini, Enrico and Bruno, Claudio and Day, John and Sansone, Valeria A and Finkel, Richard S and Mercuri, Eugenio and iSMAC/international SMA consortium, iSMAC/international SMA consortium},
  title = {Longitudinal Assessment of 4‐Year HFMSE Changes in SMA II and III Patients Treated With Nusinersen},
  journal = {European Journal of Neurology},
  year = {2025},
  volume = {32},
  number = {7},
  doi = {10.1111/ene.70268}
}
Kostenlos starten →